Tests whether long-acting somatostatin analogues affect radiation dose to neuroendocrine tumors
Studies whether continuing somatostatin analogue drugs changes tumor radiation dose in adults with neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Key facts
- Where
- Amsterdam, NetherlandsSee the site
- Phase
- Phase 2/3
Where in Netherlands
- Antoni van LeeuwenhoekAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Netherlands Cancer Institute
- Trial code
- NCT06855095
- Record updated
- 3 March 2025
- Original description
According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.Read full original descriptionShow less
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.
Inclusion: Age ≥ 18 years; Able to provide spoken and written informed consent for the trial; Histopathological confirmed neuroendocrine tumor; Fulfill the clinical criteria for PRRT; At least one soft tissue lesion > 2 cm; Aimed administered activity of 7400 MBq; ECOG score (performance status) 0-2.
Exclusion: Not possible to discontinue LA-SSA for 4-6 weeks; Use of short-acting SSAs; Pregnancy and lactating female patients; Inability to comply to the study procedures; Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.).